Working… Menu
Trial record 1 of 2 for:    Phase 1 study of 131I-MIBG with Dinutuximab for Relapsed or Refractory Neuroblastoma
Previous Study | Return to List | Next Study

MIBG With Dinutuximab +/- Vorinostat

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03332667
Recruitment Status : Recruiting
First Posted : November 6, 2017
Last Update Posted : January 20, 2021
United Therapeutics
Information provided by (Responsible Party):
New Approaches to Neuroblastoma Therapy Consortium

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : September 2021
Estimated Study Completion Date : March 2022